The British National Formulary is the unrivalled guidance on prescribing, dispensing and administering medicines.
The BNF is the only drug formulary in the world that is both independent, and has rigorous, accredited content creation processes. It is trusted by health professionals worldwide as their primary source for minimising medication errors.
Sales and UpgradesContent Updates
Speed and safety: Provides rapid reference to essential information on the selection of safe and effective medicines for individual patients
Evidence Grading: As part of NICE accreditation recommendations, BNF content is now evidence graded to reflect the strength of evidence behind them, increasing transparency to support healthcare professionals with clinical decision making
Always up-to-date: The content is revalidated, revised, and updated on a monthly basis, making sure you have access to the very latest prescribing knowledge
Worldwide credibility: The BNF uses clinical evidence from a diverse range of sources and a network of experts, giving you the confidence to select medicines safely
*based on average data in the last 12 months
This update contains 3 significant changes, 1 dose change, 3 new monographs, and 3 deleted monographs.
Significant Changes:
• Pholcodine-containing cough and cold medicines: withdrawal from UK market as a precautionary measure [MHRA/CHM advice] (see advice in Aromatic inhalations, cough preparations and systemic nasal decongestants).
• Smallpox and mpox vaccine: updated guidance for immunisation.
• Smallpox vaccine: title changed to Smallpox and mpox vaccine.
Dose Change:
• Calcipotriol with betamethasone [update to dosing].
New Monographs:
• Lupkynis® [voclosporin].
• Orgovyx® [relugolix].
• Tecvayli® [teclistamab].
Deleted Monographs:
Botulinum toxin type B; Dipyridamole with aspirin; Pholcodine.
For further details on changes in the BNF click on https://www.medicinescomplete.com/#/content/bnf/PHP107699
This update contains 2 significant changes, 1 dose change, 5 new monographs, and 2 deleted monographs.
Significant Changes:
• Metolazone (Xaqua®): exercise caution when switching patients between metolazone preparations [MHRA/CHM advice].
• Testosterone (Testogel®): risk of harm to children following accidental exposure [MHRA/CHM advice].
Dose Change:
• Cefotaxime [update to dosing for emergency treatment of suspected bacterial meningitis or meningococcal disease, before urgent transfer to hospital].
New Monographs:
• Lamzede® [velmanase alfa].
• Livtencity® [maribavir].
• Nexviadyme® [avalglucosidase alfa].
• Perindopril erbumine with amlodipine.
• Rezurock® [belumosudil].
Deleted Monographs:
• Bleomycin.
• Vinflunine.
For further details on changes in the BNF click on https://www.medicinescomplete.com/#/content/bnf/PHP107699
This update contains 3 significant changes, 2 dose changes, 4 new monographs, and 1 new preparation.
Significant Changes:
• Genital system infections, antibacterial therapy: updated guidance for the management of uncomplicated genital chlamydia and non-gonococcal urethritis.
• Ibrutinib (Imbruvica®): new risk minimisation measures, including dose modification recommendations, due to the increased risk for serious cardiac events [MHRA/CHM advice].
• Osteoarthritis: updated guidance on management.
Dose Change:
• Azithromycin [update to dosing for uncomplicated genital chlamydia in children from 12 years old and adults, update to dosing for non-gonococcal urethritis in adults, and update to include dosing in children from 12 years old for uncomplicated gonorrhoea].
• Ceftriaxone [update to dosing for pelvic inflammatory disease].
New Monographs:
• Lunsumio® [mosunetuzumab].
• Rapibloc® [landiolol hydrochloride].
• Tezspire® [tezepelumab].
• Xenpozyme® [olipudase alfa].
New Preparations:
• Okedi® [risperidone].
For further details on changes in the BNF click on https://www.medicinescomplete.com/#/content/bnf/PHP107699
This update contains 3 significant changes, 1 dose change, and 3 new monographs.
Significant Changes:
• Dupilumab (Dupixent®): risk of ocular adverse reactions and need for prompt management [MHRA/CHM advice] (advice in dupilumab and tralokinumab; see example in dupilumab).
• Ibuprofen: updated breast-feeding advice.
• Obesity: updated guidance on management.
Dose Change:
• Ibuprofen [update to dosing for acute moderate pain]
New Monographs:
• Aethoxysklerol® [lauromacrogol 400]
• Crysvita® [burosumab]
• Mounjaro® [tirzepatide]
For further details on changes in the BNF click on https://www.medicinescomplete.com/#/content/bnf/PHP107699
This update contains 4 significant changes, 3 dose changes, 4 new monographs and 2 new preparations.
Significant Changes:
• Contraceptives, interactions: updated guidance.
• Depression: updated guidance on management.
• Hypertension: updated guidance for the management of patients with type 1 diabetes.
• Ozanimod (Zeposia®): new indication for ulcerative colitis.
Dose Changes:
• Abilify Maintena® (aripiprazole) [addition of alternative initiation dosing].
• Benlysta® (belimumab) [addition of subcutaneous dosing].
• Cimzia® (certolizumab pegol) [update to dosing for ankylosing spondylitis].
New Monographs:
• Drovelis® [drospirenone with estetrol].
• Giapreza® [angiotensin II].
• Hepcludex® [bulevirtide].
• Welireg® [belzutifan].
New Preparations:
• Efmody® [hydrocortisone]
• Okedi® [risperidone].
For further details on changes in the BNF click on https://www.medicinescomplete.com/#/content/bnf/PHP107699
This update contains 1 significant change, 4 dose changes, 4 new monographs and 2 new preparations.
Significant Change:
• Herpesvirus infections: updated guidance for post-exposure prophylaxis.
Dose Changes:
• Budesonide [update to dosing for intranasal administration for rhinitis and nasal polyps].
• Jorveza® (budesonide) [update to dosing for eosinophilic oesophagitis].
• Lacosamide [update to age range for monotherapy and adjunctive treatment of focal seizures with or without secondary generalisation].
• Melatonin [update to dosing for jet lag].
New Monographs:
• Imcivree® [setmelanotide].
• Kapruvia® [difelikefalin].
• Oxbryta® [voxelotor].
• Qinlock® [ripretinib].
New Preparations:
• Actimorph® [morphine].
• Dificlir® [fidaxomicin].
For further details on changes in the BNF click on https://www.medicinescomplete.com/#/content/bnf/PHP107699
